**Int. j. adv. multidisc. res. stud.** 2025; 5(4):1575-1578

**Received:** 02-07-2025
**Accepted:** 12-08-2025

**International Journal of Advanced Multidisciplinary Research and Studies**

**ISSN: 2583-049X**

# The Antibiotic-Resistance Era in Enterobacteriaceae: Mechanisms, Epidemiology, and Emerging Countermeasures

[1] **Kabir Shekh Mohammad,** [2] **Krishna Zoirn Abada**
[1, 2] Bacterial Aromatic Center, Zhaxta Province Quarter, Zhaka, Bangladesh

**DOI:** https://doi.org/10.62225/2583049X.2025.5.4.4798
Corresponding Author: **Krishna Zoirn Abada**

**Abstract**
Enterobacteriaceae—Gram-negative bacteria such as *Escherichia coli* and *Klebsiella pneumoniae*—are major causes of both community- and hospital-acquired infections. The rise of antibiotic resistance within this family, particularly via extended-spectrum β-lactamases (ESBLs), carbapenemases (e.g., NDM-1, KPC), and plasmid-mediated determinants, has drastically reduced treatment options. The global dissemination of resistance elements such as mcr-1 further compounds the challenge. This review synthesizes key mechanisms, including emerging heteroresistance, traces current epidemiological trends across diverse regions, and examines promising strategies such as phage therapy, rapid diagnostics, and next-generation agents. Addressing this crisis demands multidisciplinary solutions that span molecular innovation, diagnostic advancements, and stewardship strategies to mitigate the mounting threat posed by resistant Enterobacteriaceae.

**Keywords:** Enterobacteriaceae, Antibiotic Resistance, Plasmid-Mediated Resistance, Carbapenemases, ESBL, Phage Therapy

## 1. Introduction

The family *Enterobacteriaceae* comprises a diverse group of Gram-negative bacteria, many of which are part of the normal flora of the human gastrointestinal tract, including *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter spp.*, and *Proteus spp.* These organisms are also prominent opportunistic pathogens, responsible for a wide range of infections including urinary tract infections (UTIs), bloodstream infections, pneumonia, intra-abdominal infections, and neonatal sepsis, particularly in healthcare settings (Nordmann *et al*., 2011) [1]. The past two decades have witnessed a disturbing rise in the prevalence of antibiotic-resistant strains within this family, significantly complicating clinical management and elevating healthcare burdens globally.

Antibiotic resistance in *Enterobacteriaceae* is primarily mediated by mechanisms such as extended-spectrum β-lactamases (ESBLs), AmpC β-lactamases, carbapenemases (including KPC, NDM, OXA-48), efflux pumps, porin loss, and plasmid-mediated resistance genes like *mcr-1* which confer resistance to colistin—the last-resort drug (El Salabi *et al*., 2013 [2]; Poirel *et al*., 2011). The mobility of these resistance determinants, often carried on plasmids and transposons, facilitates rapid horizontal gene transfer across species and genera, accelerating the spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) phenotypes (Brolund, 2014) [5].

Epidemiological data indicate an alarming global dissemination of resistant *Enterobacteriaceae*, especially strains producing carbapenemases and ESBLs, which are now endemic in parts of Asia, the Middle East, Europe, and South America (Logan & Weinstein, 2017) [6]. In Saudi Arabia, for example, a systematic review found high resistance rates to key antibiotic classes, suggesting significant overuse and insufficient infection control measures (Arafah, 2024) [8]. Moreover, the emergence of resistance in community settings and non-human reservoirs (e.g., food animals) underscores the complexity of the problem and the need for a One Health approach (Wellington *et al*., 2013) [9].

Given the rapid evolution and clinical impact of resistance in this group, it is crucial to understand the underlying mechanisms, global patterns, and emerging strategies for containment and treatment. This review aims to provide a comprehensive overview of the current antibiotic resistance landscape in *Enterobacteriaceae*, focusing on molecular mechanisms, geographic and clinical trends, and potential countermeasures including novel therapies and diagnostic innovations.

## 2. Mechanisms of Antibiotic Resistance in Enterobacteriaceae

Antibiotic resistance in *Enterobacteriaceae* is driven by a variety of mechanisms, many of which are encoded on mobile genetic elements, enabling rapid spread within and between bacterial species. These mechanisms can be broadly classified into enzyme-mediated degradation or modification, reduced membrane permeability, active efflux, and target modification or protection. Below is a detailed review of the most significant resistance mechanisms found in this family.

### 2.1 Extended-Spectrum β-Lactamases (ESBLs)

ESBLs are enzymes capable of hydrolyzing penicillins, third-generation cephalosporins (e.g., cefotaxime, ceftazidime), and aztreonam, while remaining susceptible to β-lactamase inhibitors like clavulanic acid. Common ESBL families include TEM, SHV, and CTX-M, with CTX-M variants now dominating globally (Paterson & Bonomo, 2005) [10].

The prevalence of ESBL-producing *Enterobacteriaceae* has increased significantly in both hospital and community settings. ESBL genes are typically located on plasmids, which often co-carry resistance determinants to other antibiotic classes, such as fluoroquinolones and aminoglycosides (Rawat & Nair, 2010) [12]. This co-selection exacerbates the multidrug resistance phenotype.

### 2.2 Carbapenemases

Carbapenemases are β-lactamases that hydrolyze carbapenems, which are often used as last-resort antibiotics for treating multidrug-resistant infections. Major carbapenemase families include:

- KPC (Klebsiella pneumoniae carbapenemase) – class A serine β-lactamase, endemic in the United States and increasingly worldwide.
- NDM (New Delhi metallo-β-lactamase) – class B metallo-enzyme first identified in India and now globally distributed.
- OXA-48-like enzymes – class D β-lactamases prevalent in parts of Europe and the Middle East (Nordmann *et al*., 2011) [1].

These enzymes are usually plasmid-encoded, enabling rapid interspecies dissemination. The presence of carbapenemases often results in high-level resistance and limits treatment options significantly.

### 2.3 AmpC β-Lactamases

Unlike ESBLs, AmpC β-lactamases can hydrolyze cephamycins (e.g., cefoxitin) and are not inhibited by clavulanic acid. AmpC production may be chromosomally encoded (e.g., in *Enterobacter cloacae*) or plasmid-mediated, which is of greater concern due to its mobility (Jacoby, 2009) [13]. Plasmid-mediated AmpC genes such as *bla_CMY*, *bla_DHA*, and *bla_FOX* are increasingly reported.

### 2.4 Plasmid-Mediated Colistin Resistance (mcr Genes)

The reintroduction of colistin as a last-line agent against carbapenem-resistant strains was undermined by the discovery of mcr-1, the first plasmid-mediated colistin resistance gene, in 2015 in *E. coli* from pigs and humans in China (Liu *et al*., 2016) [14]. Since then, multiple variants (mcr-1 to mcr-10) have been reported globally, including from clinical, veterinary, and environmental sources.

The mobility of mcr genes poses a major threat to global health, as colistin is often considered a drug of last resort for CRE infections.

### 2.5 Efflux Pumps and Porin Loss

Efflux pumps like AcrAB-TolC and MdfA can expel a wide range of antibiotics, including tetracyclines, chloramphenicol, and fluoroquinolones. Overexpression of these pumps contributes to multidrug resistance and often occurs alongside other mechanisms (Piddock, 2006) [15].

Additionally, loss or modification of outer membrane porins (e.g., OmpK35 and OmpK36 in *K. pneumoniae*) decreases antibiotic uptake, particularly β-lactams, and often coexists with enzyme production to amplify resistance (Tsai *et al*., 2011) [16].

### 2.6 Target Modification and Protection

Some *Enterobacteriaceae* develop resistance through mutation or modification of antibiotic targets:

- Fluoroquinolone resistance typically arises from mutations in DNA gyrase (gyrA) and topoisomerase IV (parC).
- Aminoglycoside resistance may involve methylation of 16S rRNA or enzymatic modification (e.g., acetylation, phosphorylation).
- Trimethoprim resistance stems from alterations in the dihydrofolate reductase enzyme, often via horizontally transferred *dfr* genes (Schwarz *et al*., 2004) [17].

## 3. Epidemiology and Global Spread of Antibiotic-Resistant Enterobacteriaceae

The global emergence and spread of antibiotic-resistant *Enterobacteriaceae* represents one of the most pressing threats to public health in the 21st century. Over the past two decades, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains have transitioned from being localized to endemic, and in some cases, pandemic. This section outlines key epidemiological trends in resistance, geographic distribution, and important public health insights drawn from global surveillance data.

### 3.1 Global Trends in Resistance

According to data from the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), resistance in *Enterobacteriaceae*—particularly *Escherichia coli* and *Klebsiella pneumoniae*—has been steadily rising in both high-income and low- and middle-income countries (WHO, 2023) [18]. Resistance to third-generation cephalosporins, fluoroquinolones, and carbapenems has become increasingly common, rendering many standard treatments ineffective.

- In the United States, carbapenem-resistant *Enterobacteriaceae* (CRE) infections increased fivefold from 2008 to 2012, with a concurrent rise in ESBL-producing isolates (Logan & Weinstein, 2017) [6].
- Europe has reported similar trends, with *K. pneumoniae* resistant to carbapenems found in up to 30% of isolates in some countries (ECDC, 2023).
- In low-resource settings, such as parts of Sub-Saharan Africa and South Asia, resistance rates are often higher due to over-the-counter antibiotic access, poor

stewardship, and inadequate infection control (Laxminarayan *et al*., 2016).

### 3.2 Regional Case Studies
#### 3.2.1 Middle East and North Africa (MENA)
Resistance in *Enterobacteriaceae* is particularly high across MENA countries, driven by a combination of overprescription, self-medication, and weak surveillance systems.In Saudi Arabia, a systematic review covering 17,027 isolates revealed widespread resistance to cephalosporins, aminoglycosides, and fluoroquinolones. Notably, carbapenem resistance was found in over 20% of *K. pneumoniae* isolates (Arafah, 2024) [8]. In Egypt, *E. coli* and *K. pneumoniae* strains isolated from poultry, food products, and clinical sources showed high rates of multidrug resistance, including the presence of *bla_NDM* and *mcr-1* genes (El-Tarabili *et al*., 2023) [20]. In Iraq, the epidemiological landscape of antibiotic-resistant *Enterobacteriaceae* mirrors the concerning trends seen globally, particularly in conflict-affected regions. Several local studies have highlighted the widespread emergence of multidrug-resistant (MDR) strains in both community and hospital settings. Research from Sulaimani Teaching Hospital revealed that *Escherichia coli* isolates from urinary tract infections commonly harbor β-lactamase genes, showing notable resistance to third-generation cephalosporins and carbapenems (Hama-Soor *et al*., 2021) [7]. Similarly, molecular studies on *Klebsiella pneumoniae* have reported the emergence of novel variants of blaSHV, contributing to extended-spectrum β-lactamase (ESBL) production and therapeutic failures (Hama Soor, 2022) [11]. In parallel, *Proteus spp.* isolates from clinical settings in Kurdistan have demonstrated the presence of diverse β-lactamase genes, confirming their role in multidrug resistance patterns (Salih *et al*., 2019) [23]. Although *Pseudomonas aeruginosa* is not an Enterobacteriaceae member, findings from Sulaymaniyah hospitals further underscore the broader antimicrobial resistance problem in Iraq, where carbapenem-resistant organisms are being increasingly reported (Seenaa *et al*., 2024) [4]. These findings point to the widespread dissemination of resistance genes across genera and clinical environments, driven by the overuse of antibiotics, limited diagnostic infrastructure, and lack of stewardship programs. Given the scale and genetic diversity of resistant isolates reported, Iraq represents a critical node in the regional and global antimicrobial resistance network.

#### 3.2.2 South Asia
South Asia is considered a major reservoir for mobile resistance genes such as *bla_NDM-1*. The first identification of NDM-1 was in a patient in India, and since then it has spread rapidly across the globe (Kumarasamy *et al*., 2010) [21]. Colistin resistance genes (*mcr-1*) have also been reported in this region, highlighting its role in the evolution of resistance mechanisms.

#### 3.2.3 Europe and North America
The European Centre for Disease Prevention and Control (ECDC) reports that carbapenem-resistant *Enterobacteriaceae* (particularly *K. pneumoniae*) are endemic in countries like Italy and Greece. Meanwhile, ESBL-producing *E. coli* is widespread across community settings in both Europe and North America (ECDC, 2023; Logan *et al*., 2014 [22]).

### 3.3 Community vs. Healthcare Settings
While historically concentrated in hospitals and long-term care facilities, resistant *Enterobacteriaceae* are increasingly being detected in community settings, especially in urinary tract infections. This blurring of boundaries increases the risk of transmission and complicates infection control Community-acquired ESBL-*E. coli* is particularly concerning among healthy individuals, often linked to international travel and food chain exposure (Rogers *et al*., 2014). Hospitals remain hotspots for CRE, with outbreaks often related to invasive devices, prolonged hospital stays, and inadequate sanitation.

### 3.4 One Health Considerations
The One Health framework—which integrates human, animal, and environmental health—is critical for understanding the spread of resistance in *Enterobacteriaceae*. Studies have shown:

- Resistant strains in livestock and poultry are often genetically similar to those found in human infections.
- Contaminated water systems and improperly treated waste from hospitals and farms act as environmental reservoirs for MDR *Enterobacteriaceae* (Wellington *et al*., 2013) [9].

Global interconnectedness means resistance arising in one sector or region can rapidly spread across borders. This highlights the need for coordinated international surveillance, antimicrobial stewardship, and infection prevention policies.

## 4. Conclusion
The epidemiology of resistant *Enterobacteriaceae* reflects a dynamic interplay of human behavior, microbial evolution, and health system infrastructure. While resistance is widespread globally, regional variations reveal the impact of local practices and policies. Future efforts must prioritize integrated, global surveillance and multidisciplinary interventions to contain further spread. Antibiotic resistance in *Enterobacteriaceae* is a multifactorial and evolving phenomenon. The integration of plasmid-encoded resistance genes with chromosomal mutations results in strains that are not only resistant to single agents but to multiple drug classes. This section provides a mechanistic foundation for understanding the clinical and epidemiological patterns of resistance explored in the next section.

## 5. References
1. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011; 17(10):1791-1798.
2. El Salabi A, Walsh TR, Chouchani C. Extended-spectrum β-lactamases, carbapenemases and mobile genetic elements responsible for antibiotic resistance in gram-negative bacteria. Crit Rev Microbiol. 2013; 39(2):113-122.
3. Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev. 2017; 30(2):557-596.
4. Seenaa MA, Mohammed AM, Amin SM, Ibrahim KH, Hassan SM. Distribution and molecular characterization of antibiotic-resistant *Pseudomonas aeruginosa* in

hospital settings of Sulaymaniyah, Iraq. Pol J Microbiol. 2024; 73(4):467-473. Doi: 10.33073/pjm-2024-037
5. Brolund A. Overview of ESBL-producing Enterobacteriaceae from a Nordic perspective. Infect Ecol Epidemiol. 2014; 4:22924.
6. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: The impact and evolution of a global menace. J Infect Dis. 2017; 215(suppl_1):S28-S36.
7. Hama-Soor TA, Salih SS, Muhamad SJ. The β-lactamase profile of *Escherichia coli* isolates from patients with urinary tract infections in Teaching Hospital in Sulaimani, Iraq. Ann Parasitol. 2021; 67(4):659-670. Doi: 10.17420/ap6704.382
8. Arafah AA. Antibiotic Resistance Trends Among Enterobacteriaceae in Saudi Arabia: A Systematic Review, 2024.
9. Wellington EMH, Boxall AB, Cross P, Feil EJ, Gaze WH, Hawkey PM, *et al*. The role of the natural environment in the emergence of antibiotic resistance in Gram-negative bacteria. Lancet Infect Dis. 2013; 13(2):155-165.
10. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev. 2005; 18(4):657-686.
11. Hama Soor TA. A new variant of blaSHV has been revealed in *Klebsiella pneumoniae* in Sulaimani/Iraq. Appl Ecol Environ Res. 2022; 20(5):4031-4038. Doi: 10.15666/aeer/2005_40314038
12. Rawat D, Nair D. Extended-spectrum β-lactamases in Gram Negative Bacteria. J Glob Infect Dis. 2010; 2(3):263-274.
13. Jacoby GA. AmpC β-lactamases. Clin Microbiol Rev. 2009; 22(1):161-182.
14. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, *et al*. Emergence of plasmid-mediated colistin resistance mechanism mcr-1 in animals and human beings in China: A microbiological and molecular biological study. Lancet Infect Dis. 2016; 16(2):161-168.
15. Piddock LJV. Multidrug-resistance efflux pumps-not just for resistance. Nat Rev Microbiol. 2006; 4(8):629-636.
16. Tsai YK, Fung CP, Lin JC, Chen JH, Chang FY, Chen TL, *et al*. *Klebsiella pneumoniae* outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence. Antimicrob Agents Chemother. 2011; 55(4):1485-1493.
17. Schwarz S, Kehrenberg C, Walsh TR. Use of antimicrobial agents in veterinary medicine and resistance development in zoonotic pathogens. Int J Med Microbiol. 2004; 294 Suppl:S19-S22.
18. World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report. Geneva: WHO, 2023.
19. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2023 - 2024 data. Stockholm: ECDC, 2024.
20. El-Tarabili RM, El-Sayed MA, Samir A. Prevalence and characterization of multidrug-resistant Enterobacteriaceae from animal-derived food products in Egypt. Microorganisms. 2023; 11(2):412.
21. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, *et al*. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis. 2010; 10(9):597-602.
22. Logan LK, Braykov NP, Weinstein RA, Laxminarayan R. Extended-spectrum β-lactamase-producing and third-generation cephalosporin-resistant Enterobacteriaceae in children: Trends in the United States, 1999-2011. J Pediatric Infect Dis Soc. 2014; 3(4):320-328.
23. Salih SS, Hama-Soor TA, Jalal SJ. Prevalence and molecular characterization of beta-lactamase resistance gene in multidrug resistance bacteria, Proteus spp. Kurdistan J Appl Res. 2019; Special Issue:20-28. Doi: 10.24017/science.2019.ICHMS.2
24. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: A pandemic, multiresistant, community-associated strain. J Antimicrob Chemother. 2011; 66(1):1-14.